

DALIRESP (roflumilast) PRIOR AUTHORIZATION FORM

To review the prior authorization guidelines for Daliresp (roflumilast), please refer to the Medical Assistance Prior Authorization of Pharmaceutical Services Handbook Chapter – COPD Agents (accessible at: <http://www.dhs.pa.gov/provider/pharmacyservices/drugsrequiringclinicalpriorauthorization/index.htm>).

PRIOR AUTHORIZATION INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Additional info (PA#: _____)	Prescriber name:	
<input type="checkbox"/> Renewal request	# of pages in request: _____		
Name of office contact:		Specialty:	
Contact's phone number:		State license #:	
LTC facility contact/phone:		NPI:	MA Provider ID#:
RECIPIENT INFORMATION		Street address:	
Recipient Name:		Suite #:	City/state/zip:
Recipient ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Medication requested:	<input type="checkbox"/> Daliresp 500 mcg tablet	Directions:	<input type="checkbox"/> one tablet daily	<input type="checkbox"/> other (specify): _____
Quantity:	Refills:	Diagnosis:	Dx code (required): _____	

SECTION A: INITIAL REQUESTS

1. Does the Recipient have a diagnosis of severe COPD as evidenced by all of the following? <input type="checkbox"/> medical history <input type="checkbox"/> forced expiratory volume / FEV ₁ <input type="checkbox"/> FEV ₁ / FVC ratio <input type="checkbox"/> physical exam <input type="checkbox"/> forced vital capacity / FVC	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of medical history, physical exam, and pulmonary function tests (FEV₁ & FVC)</i>
2. Does the Recipient have a diagnosis of chronic bronchitis with documented cough and sputum production for at least 3 months in the past 2 consecutive years?	<input type="checkbox"/> Yes – <i>submit documentation</i> <input type="checkbox"/> No	
3. Have other causes of chronic airflow limitations been ruled out? <input type="checkbox"/> asthma <input type="checkbox"/> bronchiectasis <input type="checkbox"/> heart failure <input type="checkbox"/> tuberculosis	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of medical history, physical exam, and pulmonary function tests</i>
4. Is the Recipient taking maximum therapeutic doses of, or have an intolerance or contraindication to, regularly scheduled use of the following? <i>Check all that apply.</i> <input type="checkbox"/> long-acting inhaled beta-2 agonist (ex. Serevent, Foradil) <input type="checkbox"/> preferred long-acting inhaled anticholinergic (ex. Spiriva, Tudorza) <input type="checkbox"/> inhaled corticosteroid (ex. Flovent, Qvar, Pulmicort, Asmanex, Breo) <input type="checkbox"/> combination product containing 2 of the above (ex. Advair, Dulera, Symbicort, Stiolto, Anoro)	<input type="checkbox"/> Yes – <i>submit medical record documentation of current, complete medication list</i> <input type="checkbox"/> No – <i>submit documentation of intolerances or contraindications to listed medications/drug classes</i>	
5. Has the Recipient experienced 2 or more COPD exacerbations in the past year that required Emergency Dept. visits, hospitalization, or treatment with oral steroids?	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit medical record documentation of all exacerbations</i>
6. Does the Recipient have moderate or severe liver impairment (Child-Pugh B or C)?	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit results of recent liver function tests (LFTs)</i>
7. Is the Recipient taking a strong CYP3A4 inducer? <input type="checkbox"/> carbamazepine <input type="checkbox"/> efavirenz <input type="checkbox"/> oxcarbazepine <input type="checkbox"/> phenytoin <input type="checkbox"/> dexamethasone <input type="checkbox"/> nevirapine <input type="checkbox"/> phenobarbital <input type="checkbox"/> rifampin	<input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of Recipient's complete current medication list</i>
8. <i>If the Recipient has a history of anxiety, bipolar disorder, depression, schizophrenia, substance use disorder, personality disorder, or prior suicide attempt</i> , was the Recipient evaluated, treated, and determined to be a candidate for Daliresp by a psychiatrist?	<input type="checkbox"/> Yes – <i>submit medical record documentation of psychiatric evaluation & treatment</i> <input type="checkbox"/> No	

SECTION B: RENEWAL REQUESTS

1. Has the Recipient experienced improvement in the signs and symptoms of COPD as evidenced by all of the following? <input type="checkbox"/> FEV ₁ <input type="checkbox"/> FEV ₁ /FVC ratio <input type="checkbox"/> decreased frequency of COPD exacerbations	<input type="checkbox"/> Yes – <i>submit medical record documentation of improvement in Recipient's condition</i> <input type="checkbox"/> No
2. Has the Recipient had a mental health screening since the last authorization of Daliresp, including an evaluation for suicidal thoughts or ideations?	<input type="checkbox"/> Yes – <i>submit medical record documentation of screening/evaluation performed since last approval</i> <input type="checkbox"/> No
3. Is the Recipient taking a strong CYP3A4 inducer? <input type="checkbox"/> carbamazepine <input type="checkbox"/> efavirenz <input type="checkbox"/> oxcarbazepine <input type="checkbox"/> phenytoin <input type="checkbox"/> dexamethasone <input type="checkbox"/> nevirapine <input type="checkbox"/> phenobarbital <input type="checkbox"/> rifampin	<input type="checkbox"/> Yes <input type="checkbox"/> No

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	Date:
------------------------------	--------------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.